Individual Neuromodulation for PDS

Launched by RUIJIN HOSPITAL · Dec 21, 2023

Keywords

ClinConnect Summary

This clinical trial is studying new treatment options for patients with Parkinsonian Syndromes (PDS), which are conditions that primarily affect movement and include disorders like progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. The goal is to see if a type of brain stimulation called neuromodulation can help improve symptoms and possibly slow down the progression of these diseases. The trial will involve 60 participants who meet specific health criteria and will be conducted at a single center.

To be eligible for this trial, participants must be between 40 and 80 years old and have been diagnosed with a Parkinsonian syndrome according to certain guidelines. They should also be stable on their current medications. Patients with serious psychiatric disorders or certain past neurological issues, as well as those with specific medical devices or who are involved in other clinical trials, will not be eligible. Those who participate can expect to receive either the active treatment or a placebo (a treatment that has no active ingredients) in a randomized manner, meaning they won’t know which one they are getting. This helps researchers understand the true effects of the treatment. Overall, this study aims to explore innovative ways to help manage PDS symptoms and improve the quality of life for affected individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Compliance with the MDS revised clinical diagnostic criteria for Parkinsonian syndrome (2015 edition)
• • aged \>40 years and \<80 years, regardless of gender.
• • Patients were relatively stable during the study period and remained stable on medication
• • Good compliance, written informed consent, and consent for NIBS long-term intervention treatment
• Exclusion Criteria:
• • Patients with severe neuropsychiatric disorders or a previous history of severe neurologic conditions (e.g., epilepsy, cerebrovascular accident, etc.) or traumatic brain injury or brain surgery
• • inability to complete the questionnaire independently
• • Previous treatment with DBS or SCS; TMS or tDCS within 6 months
• • Severe physical illness and any physical condition that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory diseases
• • Installation of intracranial stents, pacemakers, coronary stents, cochlear implants, and other human implantable materials
• • is currently taking other investigational drugs or is participating in other clinical trials
• • Any other condition that the investigator believes makes him or her unsuitable for participation in this study.